Premium
P2‐194: Potential use of cogstate battery to monitor adverse events in individuals taking part in clinical trials of anti‐amyloid drugs
Author(s) -
Maruff Paul,
Lim YenYing,
Snyder Peter J.,
Masters Colin L.,
Rowe Christopher C.,
Villemagne Victor L.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.06.733
Subject(s) - alprazolam , placebo , cognitive decline , cognition , adverse effect , medicine , clinical trial , cognitive test , disease , psychology , psychiatry , anxiety , dementia , pathology , alternative medicine
recorded. The performance quality of each participant was manually annotated and assessed based on the amount of successfully carried out tasks. Recorded data was processed by a platform of signal analysis in order to extract parameters detecting activities undertaken by the participant. We developed a classifier based on the extracted features for diagnostic prediction and further autonomy performance prediction. Results: Overall, activities and task performances were detected automatically with high accuracy rates (up to 80%). Further detailed results from the audio, gait and video analyses as well as results from a comparative analyses between the two clinical settings will be presented at the conference. Conclusions: The results suggest that it is possible to assess demetntia and pre-demented patients autonomy with the help of ICT and in particular, an automatic video monitoring, audio analyses and accelerometers and that the use of such technologies could provide clinicians with diagnostic relevant information and improve assessment in real time decreasing observer biases.